Small Cell Lung Cancer (SCLC)

Those with inflamed T cell or YAP1–positive extensive-stage small cell lung cancer were likely to gain an improvement in overall survival following treatment with durvalumab and chemotherapy vs those with other overexpressed biomarkers.

Serplulimab, which has been granted orphan drug designation by the FDA, is being considered as a treatment for patients with small cell lung cancer.

Although tiragolumab plus atezolizumab and chemotherapy missed the primary end point of progression-free survival superiority in the phase 3 SKYSCRAPER-02 trial in patients with extensive-stage small cell lung cancer, it will continue to be evaluated in non–small cell lung cancer.

Treatment with serplulimab yielded a significant improvement in overall survival in combination with chemotherapy in patients with previously untreated extensive-stage small cell lung cancer.

Compared with whole brain radiotherapy alone, the addition of local radiation boost to whole brain radiotherapy improved overall survival and progression-free survival among patients with small cell lung cancer and brain metastases.

A exposure-response analysis indicated that a 3.2mg/m2 dose of lurbinectedin every 3 weeks achieved a favorable risk/benefit profile in patients with small cell lung cancer.

On or after week 5 of treatment with chemotherapy, trilaciclib reduced the need for supportive care therapies in patients with extensive-stage small-cell lung cancer.

Patients with small cell lung cancer who failed first-line treatment within 6 months were examined for efficacy of anlotinib plus chemotherapy in a phase 2 trial whose results were presented at the 2021 ESMO Congress.

Patients with extensive-stage small cell lung cancer (ES-SCLC) derived overall survival benefit from a combination of durvalumab and chemotherapy.

Hippocampal avoidance–prophylactic cranial irradiation was associated with better cognitive function preservation versus standard prophylactic cranial irradiation for small cell lung cancer.

Two posters on the efficacy of trilaciclib for treating myelosuppression were presented at the Virtual International Society for Pharmacoeconomics and Outcomes Research 2021.

Chemotherapy-induced myelosuppression was reduced when trilaciclib was used before chemotherapy for patients with extensive-stage small cell lung cancer versus placebo.

Data from The Lancet Oncology found that higher-dose radiotherapy of 60 Gy for patients with small cell lung cancer resulted in survival benefit while maintaining the toxicity profile compared with a radiotherapy at a dose of 45 Gy.

Original research published in the journal ONCOLOGY® explored the impacts of treatment refusal in patients with small cell lung cancer.

Merck, the manufacturer of pembrolizumab, announced that it would be withdrawing the agent’s indication for the treatment of patients with previously treated SCLC.

The approval of trilaciclib was based on results from a pooled analysis of intent-to-treat datasets from 3 studies of patients with extensive-stage small cell lung cancer in which patients received standard chemotherapy plus either trilaciclib or placebo.

Racial and socioeconomic factors were associated with varying levels of survival for patients with limited-stage small cell lung cancer, with improved survival noted among African American and Asian patients compared with White patients.

Liposomal irinotecan as second-line therapy for SCLC is feasible, safe after frontline platinum therapy failure.

Updated data from a phase 2 trial of apatinib added to single-agent chemotherapy for small cell lung cancer in patients with prior treatments indicate a good efficacy and safety for the combination.

Data presented at the 2020 World Conference on Lung Cancer Singapore reported gains in survival at the population and patient levels for those with SCLC treated with immunotherapy.

Encouraging survival end points are observed with BMS-986012 plus nivolumab in immune checkpoint inhibitor–naïve SCLC, according to data presented at the 2020 World Conference on Lung Cancer.

The ongoing phase 3 CASPIAN trial evaluating the use of intravenous durvalumab, with or without tremelimumab, added to platinum–etoposide for the first-line treatment of extensive-stage small cell lung cancer demonstrated improved overall survival versus chemotherapy alone.

Nivolumab was previously granted accelerated approval by the FDA for the treatment of patients with small cell lung cancer (SCLC) whose disease had progressed after platinum-based chemotherapy and at least 1 other line of therapy, but phase 3 trial results led to a decision to withdraw the indication.

The study evaluated lurbinectedin (Zepzelca) in combination with doxorubicin versus physician's choice of topotecan or cyclophosphamide/doxorubicin/vincristine for adult patients with small cell lung cancer whose disease progressed following 1 prior platinum-containing line of therapy.

The agency granted fast track designation to irinotecan liposome injection for patients with small cell lung cancer who progressed following a first-line platinum-based regimen.

This study aimed to evaluate the prognostic impact of extrapulmonary cancers in patients with IPF, as most studies have previously focused on the effect of lung cancer on this patient population.

This study found that Black patients with extensive-stage small cell lung cancer were less likely to receive chemotherapy, as were elderly, uninsured, and those with non-private insurance.

Treatment with trilaciclib prior to chemotherapy was found to significantly reduce the need for supportive care interventions in the management of severe neutropenia and grade 3/4 anemia induced by chemotherapy in patients with extensive-stage small cell lung cancer, compared with placebo.

The FDA granted priority review to the new drug application for trilaciclib for patients with small cell lung cancer being treated with chemotherapy.

The FDA approved lurbinectedin for the treatment of adult patients with metastatic small cell lung cancer under accelerated approval based on overall response rate and duration of response in a phase 2 study.